| GTO ID | GTC2015 |
| Trial ID |
NCT03744676
|
| Disease |
B-Cell Non-Hodgkin's Lymphoma
|
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | Breyanzi|Lisocabtagene maraleucel|liso-cel|JCAR017 |
| Location approved | US, Japan, EU, Switzerland, UK, Canada |
| Generation | 2nd |
| Phase | Phase2 |
| Recruitment status | Active, Not Recruiting |
| Title | A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007) |
| Year | 2018 |
| Country | United States |
| Company sponsor | Juno Therapeutics, a Subsidiary of Celgene |
| Other ID(s) | 17007 |